Literature DB >> 35840125

Pathogenesis and Transmissibility of North American Highly Pathogenic Avian Influenza A(H5N1) Virus in Ferrets.

Joanna A Pulit-Penaloza, Jessica A Belser, Nicole Brock, Poulami Basu Thakur, Terrence M Tumpey, Taronna R Maines.   

Abstract

Highly pathogenic avian influenza A(H5N1) viruses have spread rapidly throughout North American flyways in recent months, affecting wild birds in over 40 states. We evaluated the pathogenicity and transmissibility of a representative virus using a ferret model and examined replication kinetics of this virus in human respiratory tract cells.

Entities:  

Keywords:  H5N1; avian influenza; cell culture; ferret; influenza; respiratory infections; transmission; vaccine-preventable diseases; viruses; zoonoses

Mesh:

Year:  2022        PMID: 35840125      PMCID: PMC9423912          DOI: 10.3201/eid2809.220879

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   16.126


Highly pathogenic avian influenza (HPAI) A(H5Nx) viruses (clade 2.3.4.4, primarily H5N2 and H5N8 subtypes) were first detected along the Pacific flyway in 2014, resulting in outbreaks in wild bird and domestic poultry populations in North America (). No human cases were associated with these outbreaks in the United States, but sporadic HPAI H5Nx virus human infections have been documented in other geographic locations, highlighting the potential of these viruses to jump species barriers during culling or sampling of infected birds (). Despite reduced detection of H5Nx viruses in North America in recent years, clade 2.3.4.4b H5N1 virus, which emerged and displaced other H5Nx virus in Europe, Asia, and Africa, was detected in wild birds in North America in late 2021. Since then, the virus has been introduced into all 4 flyways of North America (). The detection and spread of this virus in US commercial and backyard poultry pose substantial economic implications and concerns for human health, as evidenced by the first confirmed HPAI H5N1 human case, documented in the United States in April 2022 (), underscoring the pandemic potential presented by continued circulation of viruses at the animal–human interface. To investigate the relative risk posed by these viruses, we examined the pathogenicity and transmissibility of a representative HPAI H5N1 virus, A/American Wigeon/SC/22-000345-001/2021 (aw/SC) by using a ferret model and assessed the capacity of this virus to replicate in a human respiratory cell line compared with seasonal H1N1 viruses. We inoculated 6 ferrets with 6 log10 50% egg infectious dose (EID50) of aw/SC virus (GISAID accession no. EPI_ISL_9869760; https://www.gisaid.org) and observed them for 9 days. The animals became productively infected, but the disease was generally mild; ferrets exhibited <5% weight loss and transient fever (elevated by 1.1°C) (Table). We observed no sneezing or nasal discharge during infection. Virus replication in tissues collected on day 3 postinoculation from 3 additional ferrets was limited to the upper respiratory tract except for 1 animal that had low-level virus in the lungs. We did not detect infectious virus in blood, intestines, olfactory bulb, brain, kidneys, spleen, or liver (data not shown). That finding indicates less extensive tissue dissemination of the aw/SC virus compared with previously evaluated clade 2.3.4.4 North America H5Nx viruses, which we observed throughout the ferret respiratory tract and in some olfactory bulb and intestinal samples ().
Table

Results of ferrets inoculated with influenza A(H5N1) virus isolate A/American Wigeon/SC/22–000345–001/2021*

ParameterValue
Weight loss, %†
4.7
Temperature increase, °C‡
1.1
Nasal wash titer (peak titer days)§
4.6 (1–5)
Virus titer at day 3 postinoculation¶
Nasal wash2.4 (3/3)
Nasal turbinates3.5 (3/3)
Soft palate2.9 (3/3)
TracheaND
Lung2.2 (1/3)

*Six ferrets were inoculated with 6 log10 EID50 of A/American Wigeon/SC/22-000345-001/2021 (GISAID identical virus sequence accession no. EPI_ISL_9869760, https://www.gisaid.org; in a 1-mL volume. Three additional ferrets were inoculated and then euthanized and tested for virus titer at day 3 postinoculation. EID50, 50% egg infectious dose; ND, not detected †Percentage mean maximum weight loss within 9 days postinoculation. ‡Mean maximum rise in body temperature from baseline (37.6°C–39.4°C). §Mean maximum virus titer in nasal washes, expressed as log10 EID50/mL. ¶Viral titers are expressed as log10 EID50/mL, except for lung titer, which is expressed as log10 EID50/g of tissue. Number of ferrets with detectable virus is specified in parentheses. Limit of virus detection was 1.5 log10 EID50/mL or g.

*Six ferrets were inoculated with 6 log10 EID50 of A/American Wigeon/SC/22-000345-001/2021 (GISAID identical virus sequence accession no. EPI_ISL_9869760, https://www.gisaid.org; in a 1-mL volume. Three additional ferrets were inoculated and then euthanized and tested for virus titer at day 3 postinoculation. EID50, 50% egg infectious dose; ND, not detected †Percentage mean maximum weight loss within 9 days postinoculation. ‡Mean maximum rise in body temperature from baseline (37.6°C–39.4°C). §Mean maximum virus titer in nasal washes, expressed as log10 EID50/mL. ¶Viral titers are expressed as log10 EID50/mL, except for lung titer, which is expressed as log10 EID50/g of tissue. Number of ferrets with detectable virus is specified in parentheses. Limit of virus detection was 1.5 log10 EID50/mL or g. Next, we evaluated transmissibility of the aw/SC H5N1 virus. We detected infectious virus in nasal wash specimens among all inoculated ferrets up to day 7 postinoculation (Figure, panels A, B). Mean peak nasal wash titers (4.6 log10 EID50/mL) were comparable to those observed for the 2014 North America H5Nx isolates that did not transmit between ferrets (<4.2 log10 EID50/mL) (). However, the aw/SC virus did not transmit in a direct-contact setting (cohoused inoculated and naive ferret pairs) or through the air (ferret pairs in separate cages with perforated cage walls), as evidenced by lack of virus detection in nasal washes and lack of seroconversion of the contact ferrets to homologous virus.
Figure

Evaluating influenza A(H5N1) virus isolate aw/SC using in vivo and in vitro models. A, B) Ferrets were intranasally inoculated with 6 log10 EID50 of aw/SC virus in 1 mL of phosphate-buffered saline and direct contact (A) and respiratory droplet (B) transmission models were established with naive ferrets (1:1 ratio) the following day as described previously (). Nasal wash samples were collected from inoculated and contact ferrets every other day, and virus titers were determined in eggs (). As shown, infectious virus was detected in nasal wash specimens from all inoculated ferrets up to day 7 (left side of each panel); however, ferrets exposed only by direct contact (panel A, right) or through the air (panel B, right) did not show infectious virus. C, D) Replication kinetics of aw/SC virus were evaluated in human respiratory tract cells and compared with the H1N1 viruses, A/Michigan/45/2015 (MI/45), A/Idaho/7/2018 (ID/7), A/Nebraska/14/2019 (NE/14), and A/Nebraska/15/2018 (NE/15). Calu-3 cells (ATCC, https://www.atcc.org) were grown to confluence under submerged conditions in 12-mm diameter transwell inserts (Corning, https://www.corning.com). The cells were infected apically at a multiplicity of infection of 0.01 for 1 h and then washed and incubated at 33°C (C) or 37°C (D) as previously described (). Virus titers in triplicate cell-supernatant samples were determined by standard plaque assay in MDCK cells (). The limit of virus detection was 1.5 log10 EID50/mL or 2 log10 PFU/mL. Error bars indicate SDs. p values provided for avian H5N1 versus human seasonal H1N1 viruses were calculated by 2-way analysis of variance with a Tukey posttest. aw/SC, A/American Wigeon/SC/22-000345-001/2021; EID50, 50% egg infectious dose.

Evaluating influenza A(H5N1) virus isolate aw/SC using in vivo and in vitro models. A, B) Ferrets were intranasally inoculated with 6 log10 EID50 of aw/SC virus in 1 mL of phosphate-buffered saline and direct contact (A) and respiratory droplet (B) transmission models were established with naive ferrets (1:1 ratio) the following day as described previously (). Nasal wash samples were collected from inoculated and contact ferrets every other day, and virus titers were determined in eggs (). As shown, infectious virus was detected in nasal wash specimens from all inoculated ferrets up to day 7 (left side of each panel); however, ferrets exposed only by direct contact (panel A, right) or through the air (panel B, right) did not show infectious virus. C, D) Replication kinetics of aw/SC virus were evaluated in human respiratory tract cells and compared with the H1N1 viruses, A/Michigan/45/2015 (MI/45), A/Idaho/7/2018 (ID/7), A/Nebraska/14/2019 (NE/14), and A/Nebraska/15/2018 (NE/15). Calu-3 cells (ATCC, https://www.atcc.org) were grown to confluence under submerged conditions in 12-mm diameter transwell inserts (Corning, https://www.corning.com). The cells were infected apically at a multiplicity of infection of 0.01 for 1 h and then washed and incubated at 33°C (C) or 37°C (D) as previously described (). Virus titers in triplicate cell-supernatant samples were determined by standard plaque assay in MDCK cells (). The limit of virus detection was 1.5 log10 EID50/mL or 2 log10 PFU/mL. Error bars indicate SDs. p values provided for avian H5N1 versus human seasonal H1N1 viruses were calculated by 2-way analysis of variance with a Tukey posttest. aw/SC, A/American Wigeon/SC/22-000345-001/2021; EID50, 50% egg infectious dose. Prior evaluations of North America HPAI H5N2 and H5N8 isolates in human airway cells demonstrated that these viruses were capable of productive replication, albeit at reduced titers compared with virulent H5N1 and seasonal H1N1 viruses (). To assess whether human bronchial epithelial cells support replication of the aw/SC H5N1 virus, we compared growth kinetics of this virus with contemporary H1N1 strains at 33°C and 37°C in Calu-3 cells (ATCC, https://www.atcc.org), a cell line that permits concurrent evaluation of human and zoonotic influenza viruses for risk assessment evaluations (Figure, panels C, D) (). At 37°C, aw/SC H5N1 virus reached comparable peak mean titer to all H1N1 viruses tested by 48 hours postinoculation. However, at 33°C, aw/SC showed a substantial delay in virus replication at 24 hours postinoculation compared with all tested H1N1 strains (p<0.0001). This delay could, in part, be explained by the lack of E627K and D701N substitutions in the polymerase basic protein 2 sequence of the aw/SC virus, substitutions that are considered critical for the mammalian adaptation of avian influenza viruses (). Although we noted strain-specific differences between all viruses, the data indicate that aw/SC virus can replicate efficiently in the types of cells that woke up the human respiratory tract. The introduction of HPAI H5N1 viruses into multiple North America flyways represents a substantial concern for human health. Continued circulation of viruses in wild bird populations and repeated introduction of these viruses into gallinaceous poultry confer a multitude of opportunities for these viruses to acquire molecular features associated with enhanced mammalian fitness and human infection. Our data support the Influenza Risk Assessment Tool determination that HPAI H5N1 viruses do not pose a substantial risk to public health at this time (). However, close surveillance of circulating strains and continued assessment of new viruses are crucial to ensure strains with enhanced mammalian fitness are quickly identified.
  8 in total

1.  Intercontinental Spread of Asian-Origin H5N8 to North America through Beringia by Migratory Birds.

Authors:  Dong-Hun Lee; Mia Kim Torchetti; Kevin Winker; Hon S Ip; Chang-Seon Song; David E Swayne
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

2.  Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model.

Authors:  Taronna R Maines; Li-Mei Chen; Yumiko Matsuoka; Hualan Chen; Thomas Rowe; Juan Ortin; Ana Falcón; Tran Hien Nguyen; Le Quynh Mai; Endang R Sedyaningsih; Syahrial Harun; Terrence M Tumpey; Ruben O Donis; Nancy J Cox; Kanta Subbarao; Jacqueline M Katz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

3.  Resurgence of avian influenza virus.

Authors:  Michelle Wille; Ian G Barr
Journal:  Science       Date:  2022-04-26       Impact factor: 47.728

4.  Pathogenesis and Transmission of Novel Highly Pathogenic Avian Influenza H5N2 and H5N8 Viruses in Ferrets and Mice.

Authors:  Joanna A Pulit-Penaloza; Xiangjie Sun; Hannah M Creager; Hui Zeng; Jessica A Belser; Taronna R Maines; Terrence M Tumpey
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

5.  Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type i interferon response in polarized human bronchial epithelial cells.

Authors:  Hui Zeng; Cynthia Goldsmith; Pranee Thawatsupha; Malinee Chittaganpitch; Sunthareeya Waicharoen; Sherif Zaki; Terrence M Tumpey; Jacqueline M Katz
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

6.  Influenza: propagation, quantification, and storage.

Authors:  Kristy J Szretter; Amanda L Balish; Jacqueline M Katz
Journal:  Curr Protoc Microbiol       Date:  2006-12

Review 7.  A review of H5Nx avian influenza viruses.

Authors:  Ivette A Nuñez; Ted M Ross
Journal:  Ther Adv Vaccines Immunother       Date:  2019-02-22

8.  Intercontinental Movement of Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4 Virus to the United States, 2021.

Authors:  Sarah N Bevins; Susan A Shriner; James C Cumbee; Krista E Dilione; Kelly E Douglass; Jeremy W Ellis; Mary Lea Killian; Mia K Torchetti; Julianna B Lenoch
Journal:  Emerg Infect Dis       Date:  2022-03-18       Impact factor: 6.883

  8 in total
  1 in total

1.  Avian influenza overview June - September 2022.

Authors:  Cornelia Adlhoch; Alice Fusaro; José L Gonzales; Thijs Kuiken; Stefano Marangon; Éric Niqueux; Christoph Staubach; Calogero Terregino; Irene Muñoz Guajardo; Kateryna Chuzhakina; Francesca Baldinelli
Journal:  EFSA J       Date:  2022-10-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.